Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study

Category Primary study
JournalJournal of Diabetes Investigation
Year 2016
This article has no abstract
Epistemonikos ID: 1136077a9ab26b3887b6d3be38931e38a8ab0bd0
First added on: Feb 07, 2025